Intensive Neoadjuvant Chemotherapy Enhances Survival in Pancreatic Cancer

An analysis of 184 patients with anatomically resectable pancreatic cancer and elevated CA19-9 levels demonstrated that those receiving intensive neoadjuvant chemotherapy (NAC) showed significantly improved overall survival compared to those undergoing upfront surgery, with median survival times of 52.7 months versus 22.7 months (p < 0.001). Additionally, higher lymph node-negative resection rates and better post-resection CA19-9 normalization were observed in the NAC group, indicating its potential benefits for patients with CA19-9 > 500 U/mL.